MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/jjco/hyae073

Медицинская библиотека · Japanese journal of clinical oncology · 2024

The effect of epidermal growth factor receptor mutation on adjuvant chemotherapy with tegafur/uracil for patients with completely resected, non-lymph node metastatic non-small cell lung cancer (> 2 cm): a multicenter, retrospective, observational study as exploratory analysis of the CSPOR-LC03 study.

Miyoshi Tomohiro, Aokage Keiju, Watanabe Shun-Ichi, Ito Hiroyuki, Sakakura Noriaki, Mun Mingyon, Yamashita Motohiro, Ohde Yasuhisa, Aoki Tadashi, Nishio Wataru, Taguri Masataka, Tsuboi Masahiro

СтатьяНаблюдательное исследованиеМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND

The use of adjuvant osimertinib for epidermal growth factor receptor (EGFR) mutants is expected to expand to earlier stage I in the future, potentially competing with the current standard of care, oral tegafur/uracil (UFT), in Japan. However, the effect of EGFR mutation status on the therapeutic effect of UFT remains unclear. This study was conducted as an exploratory analysis of a retrospective observational study that investigated the real-world data of postoperative adjuvant chemotherapy in Japan (CSPOR-LC03).

METHODS

Between 2008 and 2013, 1812 patients with completely resected adenocarcinoma diagnosed as pathologic stage I (T1 > 2 cm, TNM classification, sixth edition) who have maintained organ function, and no history of other cancers were included. The primary endpoint was the 5-year disease-free survival (DFS) rate, and we compared this rate between four groups classified based on the administration of adjuvant UFT and EGFR mutation status.

RESULTS

Of the 933 (51%) patients with EGFR mutations, 394 underwent adjuvant UFT therapy. Of the 879 (49%) patients without EGFR mutations, 393 underwent adjuvant UFT therapy. The 5-year DFS of UFT+/EGFR+ and UFT-/EGFR+ patients were 82.0 and 87.1%, respectively, and those of UFT+/EGFR- and UFT-/EGFR- patients were 80.0 and 86.9%, respectively. DFS was significantly worse in the UFT+ group than in the UFT- group (P = 0.015). Adjuvant UFT therapy was not an independent prognostic factor for DFS, regardless of the EGFR mutation status.

CONCLUSION

In pathologic stage I (>2 cm) lung adenocarcinomas with EGFR mutation, the survival benefit of adjuvant UFT was not observed.

Для цитирования: Miyoshi Tomohiro, Aokage Keiju, Watanabe Shun-Ichi, Ito Hiroyuki, Sakakura Noriaki, Mun Mingyon, Yamashita Motohiro, Ohde Yasuhisa, Aoki Tadashi, Nishio Wataru, Taguri Masataka, Tsuboi Masahiro. The effect of epidermal growth factor receptor mutation on adjuvant chemotherapy with tegafur/uracil for patients with completely resected, non-lymph node metastatic non-small cell lung cancer (> 2 cm): a multicenter, retrospective, observational study as exploratory analysis of the CSPOR-LC03 study.. Japanese journal of clinical oncology. 2024. DOI: 10.1093/jjco/hyae073.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.